Korean scientists facilitates development of DNA-based medicine

Published: 2009-09-01 06:56:00

Updated: 2009-09-01 06:56:00

Viromed Co. says it administered VM202RY, DNA-based medicine for ischemic disease including peripheral and coronary artery disease, to the last patient in the phase I, dose-escalation study for 9 Korean patients.

This trial has been conducted in Seoul National University Hospital in collaborat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK